Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Devonian Health Group ( (TSE:GSD) ) has provided an update.
Devonian Health Group reported positive preclinical results showing that its lead candidate Thykamine reduced key markers of fibrosis and inflammation in a human liver-on-a-chip model of metabolic-associated steatohepatitis. The compound demonstrated dose-dependent effects on fibrosis biomarkers, collagen deposition, and pro-inflammatory cytokines, while preserving liver cell viability.
The findings bridge prior efficacy data from a mouse MASH model to a human microphysiological system, reinforcing Thykamine’s potential as a disease-modifying therapy. Devonian plans further preclinical work to characterize the drug in MASH and other fibrotic diseases, aiming to strengthen its position in a rapidly expanding global market for MASH treatments.
More about Devonian Health Group
Devonian Health Group Inc. is a Quebec-based biopharmaceutical company focused on developing innovative therapies derived from its SUPREX platform. Its lead pharmaceutical candidate, Thykamine, targets inflammatory and fibrotic conditions, positioning the company within the high-growth market for metabolic and liver diseases such as MASH.
Average Trading Volume: 1,312
Technical Sentiment Signal: Buy
Current Market Cap: C$37.2M
See more insights into GSD stock on TipRanks’ Stock Analysis page.